X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/taiho-oncology-announces-publication-of-final-results-of-the-phase-3-ascertain-clinical-trial-of-oral-decitabine-and-cedazuridine-fixed-dose-combination-inqovi-in-patients-with-mds-and-cmml-302041085.html
https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-from-a-us-real-word-study-of-oral-decitabine-and-cedazuridine-302010317.html
https://www.ema.europa.eu/en/documents/overview/inaqovi-epar-medicine-overview_en.pdf
https://www.pharmatimes.com/news/ema_accepts_application_for_leukaemia_drug_from_otsuka_and_astex_1453762
https://www.prnewswire.com/news-releases/national-comprehensive-cancer-network-adds-inqovi-decitabine-and-cedazuridine-tablets-to-its-clinical-practice-guidelines-in-oncology-for-myelodysplastic-syndromes-301178152.html
https://www.biospace.com/article/releases/astex-pharmaceuticals-expands-clinical-evaluation-of-oral-decitabine-and-cedazuridine-tablets-through-new-cooperative-research-and-development-agreement-crada-with-the-u-s-national-cancer-institute-nci-/
https://www.fiercepharma.com/drug-delivery/astex-pharmaceuticals-nabs-green-light-for-oral-chemotherapy-inqovi
https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/inqovi-approved-myelodysplastic-syndromes-mds-de-novo-secondary-mds/
https://www.otsuka.co.jp/en/company/newsreleases/2020/20200708_1.html#:~:text=of%20their%20homes-,Otsuka%20Pharmaceutical%20Co.%2C%20Ltd.,leukemia)%2C%20two%20blood%20malignancies.
Market Place
Share 
